Choice and Duration of Anticoagulation for Venous Thromboembolism

doi:10.3390/jcm13010301

Aroosa Malik, Nghi B. Ha, Geoffrey D. Barnes

Choice and Duration of Anticoagulation for Venous Thromboembolism

General Medicine

Venous thromboembolism (VTE) is a prevalent medical condition with high morbidity, mortality, and associated costs. Anticoagulation remains the main treatment for VTE, though the decision on when, how, and for how long to administer anticoagulants is increasingly complex. This review highlights the different phases of VTE management, with special circumstances for consideration such as antiphospholipid syndrome, coronary artery disease, cancer-associated thrombus, COVID-19, and future anticoagulation options. Anticoagulation management will continue to be a complex decision, applying evidence-based medicine to individual patients with the hope of maximizing effectiveness while minimizing risks.

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

Web-based, modern reference management
Collaborate and share with fellow researchers
Integration with Overleaf
Comprehensive BibTeX/BibLaTeX support
Save articles and websites directly from your browser
Search for new articles from a database of tens of millions of references

Try out CiteDrive

Choice and Duration of Anticoagulation for Venous Thromboembolism

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

More from our Archive

Virtual education strategies in the context of sustainable health care and medical education: A topic modelling analysis of four decades of research

Perinatal Depression and Risk of Suicidal Behavior

The new frontier: Clinical consequences of long COVID

The infection-tolerant white-footed deermouse tempers interferon responses to endotoxin in comparison to the mouse and rat

Hospital at Home Program for the Treatment of Pediatric Osteoarticular Infections

Xylazine in Overdose Deaths and Forensic Drug Reports in US States, 2019-2022

Feasibility and performance of in-house red blood cell reagents to detect unexpected antibodies in immunized patients in Burkina Faso

Dabrafenib and trametinib as a promising treatment option for pediatric population with low-grade gliomas that have BRAF V600E mutation; a breakthrough in the field of neuro-oncology

Exposure to Residential Green Space and Bone Mineral Density in Young Children

Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates